Phase II trial: CBM588 (microbiome modulator) with pembrolizumab (PD-1 inhibitor)

This Phase II study at City of Hope Medical Center evaluates the addition of probiotic CBM588 to pembrolizumab versus pembrolizumab alone as adjuvant therapy in resected high-risk renal cell carcinoma. Patients receive post-surgery immunotherapy and serial imaging with blood tests to monitor recurrence, with CBM588 aiming to modulate the microbiome to potentially enhance immune response and reduce disease relapse.